Type 1 Diabetes Clinical Trials

59 studies are recruiting for type 1 diabetes in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes

   This is a decentralized observational clinical registry to collect real-world evidence related to the safety and effectiveness of the Omnipod 5 system in children and adults with Type 1 Diabetes.

   Stage

   Not phased

   Ages

   2 and older

   Site

   Circuit Clinical, Buffalo, New York

   Run by

   Insulet Corporation

   See if you can join NCT06144554 on ClinicalTrials.gov

2. Transdisciplinary Care for Young Adults With Type 1 Diabetes

   The incidence of type 1 diabetes (T1D) is increasing globally with the most substantial increases occurring in the youngest age groups. A growing number of youths with T1D must therefore transition their healthcare from pediatric to adult T1D care settings as they approach young adulthood. This hea…

   Stage

   Not phased

   Ages

   17 and older

   Site

   Nemours Children's Health, Delaware, Wilmington, Delaware

   Locations

   2 in total

   Run by

   Nemours Children's Clinic

   See if you can join NCT06172166 on ClinicalTrials.gov

3. Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes

   The objectives of this study are to examine how sex hormones (use of hormonal birth control, menstrual cycle phase) impact glycemic control among women with type 1 diabetes (T1D), and to test adjustments to insulin dosing and food intake to ameliorate cycle-related glycemic variability. A secondary…

   Stage

   Not phased

   Ages

   18 to 45

   Site

   University of Colorado, Aurora, Colorado

   Run by

   University of Colorado, Denver

   See if you can join NCT06297980 on ClinicalTrials.gov

4. Accuracy of Continuous Glucose Monitors During the Perioperative Period in Youth With Type 1 Diabetes

   This study is assessing the accuracy of continuous glucose monitors during surgical procedures requiring anesthesia.

   Stage

   Not phased

   Ages

   2 to 26

   Site

   Barbara Davis Center, Aurora, Colorado

   Run by

   University of Colorado, Denver

   See if you can join NCT06575842 on ClinicalTrials.gov

5. Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

   The primary objective of this study is to determine the effects of semaglutide on change in albuminuria from baseline to 26 weeks in type 1 diabetes. The secondary objective is to determine the effects of semaglutide on change in kidney parameters (including kidney oxygenation and function) measure…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Colorado Anschutz Medical Campus, Aurora, Colorado

   Locations

   4 in total

   Run by

   University of Washington

   See if you can join NCT05822609 on ClinicalTrials.gov

6. ACT1VATE: Addressing Emotional Distress to Improve Outcomes Among Diverse Adults With Type 1 Diabetes

   This research will compare a psychological intervention ("ACT1VATE") versus diabetes self-management education and support (DSME/S; usual care) in improving clinical, behavioral, psychosocial, process, and cost outcomes among adults with poorly controlled type 1 diabetes (T1D) who are experiencing …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Scripps Whittier Diabetes Institute, San Diego, California

   Run by

   Scripps Whittier Diabetes Institute

   See if you can join NCT04933851 on ClinicalTrials.gov

7. Type 1 Diabetes Adolescents for Healthier Lifestyles Study

   Before the 1990s, obesity was rare among young people with type 1 diabetes (T1D), but now it is more common. Recent studies show that over 50% of young people with T1D will have overweight or obesity within five years of being diagnosed with T1D. Both obesity and T1D increase the risk of heart dise…

   Stage

   Not phased

   Ages

   13 to 18

   Site

   Weight Control and Diabetes Research Center, Providence, Rhode Island

   Run by

   The Miriam Hospital

   See if you can join NCT06878872 on ClinicalTrials.gov

8. Impact of Obesity on Microvascular Insulin Action and Cardiorespiratory Fitness in Type 1 Diabetes

   The purpose of this study is: * To see if insulin resistance (how sensitive your muscle tissue is to insulin) is associated with lower cardio fitness in people with Type 1 diabetes compared to healthy controls, before and after a High Intensity Interval Training (HIIT) exercise program. * To see if…

   Stage

   Not phased

   Ages

   21 to 50

   Site

   University of Virginia, Charlottesville, Virginia

   Run by

   University of Virginia

   See if you can join NCT07573228 on ClinicalTrials.gov

9. Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)

   PRISM-TID is a single center non-inferiority randomized controlled trial of permissive intrapartum glucose management (intervention) versus strict intrapartum glucose management (standard of care) among pregnant individuals with type 1 diabetes (T1D) using hybrid closed loop therapy (HCL) who are a…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine, Columbus, Ohio

   Run by

   Ohio State University

   See if you can join NCT07293715 on ClinicalTrials.gov

10. A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500

    The goal of this clinical trial is to assess the safety of a new U500 insulin formulation and to determine how rapidly it is absorbed and how long it takes to act when administered intraperitoneally. The trial will be conducted in people with Type 1 Diabetes. The main questions it aims to answer ar…

    Stage

    Phase 1

    Ages

    18 to 60

    Site

    ProSciento, Inc., Chula Vista, California

    Run by

    Portal Diabetes, Inc.

    See if you can join NCT07341373 on ClinicalTrials.gov

11. Registry for Stage 2 Type 1 Diabetes

    Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to del…

    Stage

    Not phased

    Ages

    Any age

    Site

    University of California Los Angeles Health- Site Number : 8400020, Los Angeles, California

    Locations

    37 in total

    Run by

    Sanofi

    See if you can join NCT06481904 on ClinicalTrials.gov

12. Immune Function and the Progression to T1D

    To elucidate the mechanisms by which type 1 diabetes-associated genes; IFIH1, TYK2, IKZF4, as well as total genetic risk, impart functional immunoregulatory abnormalities that result in expansion of self-reactive adaptive immune cells, defective regulatory/effector mechanisms in T cells, inflammato…

    Stage

    Not phased

    Ages

    0 to 100

    Site

    Kieran McGrail, Gainesville, Florida

    Locations

    3 in total

    Run by

    University of Florida

    See if you can join NCT05899439 on ClinicalTrials.gov

13. An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

    This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Perelman Center for Advanced Medicine - Endocrinology, Philadelphia, Pennsylvania

    Locations

    7 in total

    Run by

    Vertex Pharmaceuticals Incorporated

    See if you can join NCT06832410 on ClinicalTrials.gov

14. Home-based Oral Glucose Tolerance Test for Type 1 Diabetes Screening

    This study aims at quantifying the accuracy of a self-administered fingerstick based glucose tolerance test (GTT@Home) respect to the gold-standard in-clinic venous plasma measures during the oral glucose tolerance test (OGTT) across a wide range of glycemic values in people at risk for clinical ty…

    Stage

    Not phased

    Ages

    8 to 45

    Site

    Yale University Pediatric and Adult Diabetes Clinic, New Haven, Connecticut

    Run by

    Yale University

    See if you can join NCT07155252 on ClinicalTrials.gov

15. General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery

    In partnership with Helmsley Charitable Trust, the Sanford PLEDGE Study is a large-scale, observational, feasibility study of general population screening for T1D and celiac autoantibodies. Screening is incorporated into routine health care visits within an integrated health system.

    Stage

    Not phased

    Ages

    Up to 17

    Site

    Sanford Bemidji Region Clinics, Bemidji, Minnesota

    Locations

    4 in total

    Run by

    Sanford Health

    See if you can join NCT04477928 on ClinicalTrials.gov

16. Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes

    This study will examine the potential cardiovascular effect(s) of artificial pancreas (AP) technology in patients with type 1 diabetes. AP technology is a system of devices that closely mimics the glucose-regulating function of a healthy human pancreas. It includes an insulin pump and a continuous …

    Stage

    Not phased

    Ages

    18 to 40

    Site

    University of Virginia Health System, Charlottesville, Virginia

    Run by

    University of Virginia

    See if you can join NCT05653518 on ClinicalTrials.gov

17. Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes

    The brief purpose of this research study is to learn about the safety and efficacy of intra-arterial administration of CELZ-201 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D).

    Stage

    Phase 1

    Ages

    18 to 35

    Site

    Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida

    Run by

    Creative Medical Technology Holdings Inc

    See if you can join NCT05626712 on ClinicalTrials.gov

18. Effect of C-peptide on Hypoglycemic Counterregulation

    Iatrogenic hypoglycemia is the most prominent barrier to the safe, effective management of blood sugar in people with type 1 diabetes due to periodic over-insulinization. During insulin-induced hypoglycemia, glucagon secretion is diminished in type 1 diabetes which, in turn, reduces hepatic glucose…

    Stage

    EARLY_Phase 1

    Ages

    18 to 40

    Site

    University of Cincinnati, Cincinnati, Ohio

    Run by

    University of Cincinnati

    See if you can join NCT06470295 on ClinicalTrials.gov

19. Lipoprotein Kinetics in T1D

    The purpose of this research study is to understand how type 1 diabetes (T1D) increases the risk for cardiovascular diseases (heart attack and stroke). To this end, the investigators will compare apolipoprotein and triglyceride kinetics in people wtih T1D and healthy control participants.

    Stage

    Not phased

    Ages

    18 to 45

    Site

    University of Missouri School of Medicine, Columbia, Missouri

    Run by

    University of Missouri-Columbia

    See if you can join NCT05179954 on ClinicalTrials.gov

20. Discovery Diabetes

    The goal of this clinical trial is to learn if the Discovery Program can help improve diabetes management in adolescents and young adults with type 1 diabetes (T1D). The main questions it aims to answer are: Does the Discovery Program lead to better glycemic control as measured by HbA1c levels? How…

    Stage

    Not phased

    Ages

    13 to 21

    Site

    Vanderbilt University, Nashville, Tennessee

    Run by

    Vanderbilt University Medical Center

    See if you can join NCT07116434 on ClinicalTrials.gov

21. GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab

    The goal of this study is to determine how a drug class called glucagon-like peptide-1 receptor agonists (GLP-1Ra) affects people during an early stage of Type 1 Diabetes undergoing clinical teplizumab treatment. This study involves giving participants a liquid meal under different conditions and o…

    Stage

    EARLY_Phase 1

    Ages

    12 to 50

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Run by

    Vanderbilt University Medical Center

    See if you can join NCT06338553 on ClinicalTrials.gov

22. InvesT1D: Promoting Adolescent Investment in Diabetes Care

    The goal of this clinical trial is to see if a financial incentives program called InvesT1D is helpful to support diabetes management in adolescents with type 1 diabetes. Adolescent participants will be randomized to usual care or receive financial incentives for meeting diabetes self-management an…

    Stage

    Not phased

    Ages

    12 and older

    Site

    Seattle Children's, Seattle, Washington

    Run by

    Harvard Pilgrim Health Care

    See if you can join NCT06384911 on ClinicalTrials.gov

23. A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States

    This study is an observational, longitudinal, non-interventional real-world study in the United States. The study is meant to describe the experience of participants with a history of stage 2 type 1 diabetes who have been infused with teplizumab and the experience of participants with stage 2 type …

    Stage

    Not phased

    Ages

    8 and older

    Site

    Investigational Site, San Francisco, California

    Run by

    Sanofi

    See if you can join NCT07260110 on ClinicalTrials.gov

24. Precision Administration of Anti-thymocyte Globulin With or Without Verapamil

    T cell directed therapy, anti-thymocyte globulin (ATG), in low doses, has been shown to lower HbA1c and preserve endogenous insulin production (measured by C-peptide) in individuals with recently diagnosed type 1 diabetes (T1D). However, not all individuals who received ATG responded to the therapy…

    Stage

    Phase 2

    Ages

    6 to 35

    Site

    Barbara Davis Center for Diabetes, Aurora, Colorado

    Locations

    2 in total

    Run by

    University of Florida

    See if you can join NCT06455319 on ClinicalTrials.gov

25. Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression

    This project will evaluate a telemedicine-delivered, Unified Protocol for Cognitive-Behavioral Therapy (UP-CBT) enhanced with continuous glucose monitor (CGM) review to target anxiety and depressive symptoms and glycemic control in adults with type 1 diabetes.

    Stage

    Not phased

    Ages

    18 to 64

    Site

    Boston University, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Albert Einstein College of Medicine

    See if you can join NCT05734313 on ClinicalTrials.gov